International
The Morning Science

What science found today

‹
 

Research

Experimental GLS-1 inhibitor demonstrates antitumor activity in advanced treatment-resistant ovarian cancer

Medical Xpress ·

Experimental GLS-1 inhibitor demonstrates antitumor activity in advanced treatment-resistant ovarian cancer

The Brief

  • A Phase I trial tested the experimental GLS-1 inhibitor IACS-6274 combined with bevacizumab and paclitaxel chemotherapy in patients with advanced platinum-resistant ovarian cancer.
  • Researchers presenting the new results reported promising antitumor activity for the combination.

Why it matters

Early-phase signals of activity for a GLS-1 inhibitor combination in treatment-resistant ovarian cancer are relevant to researchers following metabolic approaches to cancer therapy.

Who’s affected

  • oncology researchers
  • clinicians and patients with platinum-resistant ovarian cancer

Combining the experimental therapy IACS-6274 with targeted therapy bevacizumab and paclitaxel chemotherapy showed promising antitumor activity in a Phase I trial of patients with advanced platinum-resistant ovarian cancer, according to new results presented by researchers from…

How do you feel about this?

0 Comments

    Experimental GLS-1 inhibitor demonstrates antitumor activity in advanced treatment-resistant ovarian cancer – The Morning Science